samedan logo

 
 
spacer
home > ict > winter 2019 > improving outcomes in diabetes research
PUBLICATIONS
International Clinical Trials

Improving Outcomes in Diabetes Research

Diabetes is often referred to as an epidemic, with an estimated 415 million adults worldwide living with the condition, according to the International Diabetes Federation Diabetes Atlas – approximately 1 in 11 of the adult population (1). What’s more, this figure is expected to rise to 642 million people worldwide by 2040. With a reported 46% of people with diabetes undiagnosed, these figures are, realistically, much higher.

With so much of the population suffering, pharmaceutical companies are continuing to invest in research into this condition in a bid to bring new and improved treatments to market across the globe. With this in mind, this article will discuss the current status of diabetes clinical research. In particular, it will provide an overview of the current diabetes landscape, including the types of disease and condition management, as well as the challenges of clinical research. Putting the person with diabetes at the heart of the development process will demonstrate how sponsors can implement patient-centric electronic data capture solutions which improve the user experience and support better study outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Katie Garner is the Therapeutic Areas Advisor at CRF Bracket. She is responsible for providing specific therapeutic advice and supporting the therapeutic, sales, marketing, and product development teams. Previously, Katie worked as a Project Manager for a health outcomes consultancy and at the NHS Purchasing and Supply Agencies Centre for Evidence-Based Purchasing. She has also worked for the Medicine and Healthcare products Regulatory Agency as a Senior Medical Device Specialist, responsible for the safety and regulation of in vitro diagnostic and contraceptive medical devices.
spacer
Katie Garner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement